Transaction DateRecipientSharesTypePriceValue
25th February 2021Steve Hoffman41,750Open or private sale$2.13$88,927.50
24th February 2021Steve Hoffman41,750Open or private sale$2.22$92,685.00
22nd February 2021Michael Demurjian20,000Open or private sale$2.43$48,614.00
16th February 2021Michael Demurjian20,000Open or private sale$2.77$55,376.00
8th February 2021Michael Demurjian20,000Open or private sale$2.45$49,000.00
1st February 2021Michael Demurjian20,000Open or private sale$1.69$33,786.00
25th January 2021Michael Demurjian20,000Open or private sale$2.07$41,426.00
22nd January 2021Steve Hoffman45,250Open or private sale$1.72$77,830.00
21st January 2021Steve Hoffman56,250Open or private sale$1.89$106,312.50
6th January 2021Steve Hoffman56,250Open or private sale$1.41$79,312.50
Tyme Technologies
Tyme Technologies logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 6/10.


Tyme Technologies, Inc. is a biotechnology company. It engages in the development and commercialization of cancer therapies. It offers a clinical program named SM-88 which is a novel, oral, and monotherapy investigational agent.


Ticker: TYME
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1537917
Employees: 18
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals